Literature DB >> 9186847

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.

T T Aye1, A Bartholomeusz, T Shaw, S Bowden, A Breschkin, J McMillan, P Angus, S Locarnini.   

Abstract

BACKGROUND/AIMS: The purpose of this study was to investigate possible resistance mutations which arose in the polymerase gene of hepatitis B virus (HBV) in a patient with severe recurrent HBV infection following liver transplantation. The patient's management included antiviral chemotherapy for almost 4 years comprising ganciclovir, foscarnet and famciclovir. In the last 2.5 years of famciclovir treatment, an increase in serum HBV DNA levels and a reduced sensitivity of the virion-associated DNA polymerase to penciclovir triphosphate were observed.
METHODS: The viral polymerase gene and X gene were sequenced from serum samples collected at representative time intervals covering the entire treatment period.
RESULTS: No mutations were detected in the X gene. Three nucleotide mutations, each of which resulted in an altered amino acid sequence, were detected in the polymerase gene after 816 days of total antiviral therapy (370 days of famciclovir). Two of these mutations were detected by direct sequencing and the third was detected after cloning and was present in 10% of the clones. All three mutations occurred in "region B" of RNA-dependent DNA polymerases. The HBV polymerase has similarities to both RNA and DNA polymerases. These mutations in the HBV polymerase gene were located in a similar area to the penciclovir-induced mutations observed in the herpes simplex virus DNA polymerase gene.
CONCLUSIONS: Three mutations within the HBV polymerase gene were detected which were associated with a reduced penciclovir sensitivity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9186847     DOI: 10.1016/s0168-8278(97)80125-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  25 in total

1.  In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir.

Authors:  D Colledge; G Civitico; S Locarnini; T Shaw
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 2.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

3.  Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.

Authors:  W E Delaney; R Edwards; D Colledge; T Shaw; J Torresi; T G Miller; H C Isom; C T Bock; M P Manns; C Trautwein; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 4.  Immune escape by hepatitis B viruses.

Authors:  U Protzer; H Schaller
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

5.  Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: frequency and functional consequences of PCR-introduced mutations.

Authors:  S Günther; G Sommer; F Von Breunig; A Iwanska; T Kalinina; M Sterneck; H Will
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

6.  Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus.

Authors:  P A Cane; P Cook; D Ratcliffe; D Mutimer; D Pillay
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

7.  Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir.

Authors:  R T Sarisky; M R Quail; P E Clark; T T Nguyen; W S Halsey; R J Wittrock; J O'Leary Bartus; M M Van Horn; G M Sathe; S Van Horn; M D Kelly; T H Bacon; J J Leary
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

8.  Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Authors:  D J Tenney; S M Levine; R E Rose; A W Walsh; S P Weinheimer; L Discotto; M Plym; K Pokornowski; C F Yu; P Angus; A Ayres; A Bartholomeusz; W Sievert; G Thompson; N Warner; S Locarnini; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

Authors:  William E Delaney; Huiling Yang; Christopher E Westland; Kalyan Das; Eddy Arnold; Craig S Gibbs; Michael D Miller; Shelly Xiong
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue.

Authors:  A J Nicoll; D L Colledge; J J Toole; P W Angus; R A Smallwood; S A Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.